<DOC>
	<DOC>NCT01422590</DOC>
	<brief_summary>1. Explore pharmacodynamics - glucose - insulin - C-peptide - glucagon - intact GLP-1 - DPP-4 activity - CGMS (continuous glucose monitoring system) 2. Assess Safety - adverse events - clinical laboratory test - physical examination</brief_summary>
	<brief_title>Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin</brief_title>
	<detailed_description>Pharmacodynamic assessment - CGMS data is obtained from day 1 to day 3 (48 hours) - PD is measured before (day 1) and after drug administration (day 2) 1. AUC of glucose, insulin, C-peptide, glucagon, intact GLP-1, DPP-4 activity 2. MAGE (mean amplitude of glycemic excursion) from CGMS data</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male or female patients with type 2 diabetes mellitus 6.5% ≤ HbA1c &lt; 9.0% Stopped treatment of sulfonylurea and biguanide for more than 8 weeks Stopped treatment of other antidiabetic agents for more than 12 weeks 16 kg/m2 ≤ body mass index &lt; 30 kg/m2 Fasting glucose ≥ 200 mg/dL Required insulin therapy Patients with neuropathy, retinopathy or renopathy Contraindicated for mitiglinide or sitagliptin</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>sitagliptin</keyword>
	<keyword>mitiglinide</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
</DOC>